Physician profile
Jessica E Lee
NPI 1477264745
$1,608.13
in general payments reported to CMS, 2019-2025
13 companies · $23.35 in 2025
The $23.35 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $654 · 2024: $931 · 2025: $23.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $319.33 | 2023-2024 | |
| Novo Nordisk INC | $316.77 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $178.59 | 2023-2024 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.02 | 2024 | Jardiance |
| Abbvie INC. | $149.17 | 2023-2025 | |
| Esperion Therapeutics, INC. | $131.53 | 2024 | Nexletol, Nexlizet |
| Astellas Pharma US INC | $118.86 | 2023 | Veozah |
| Lilly USA, LLC | $85.26 | 2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $47.78 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $40.42 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.51 | 2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $20.56 | 2024 | Xarelto |
| Seqirus USA INC | $17.33 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.